Loading…
Employees: 1,240
Size LifeTech Scientific (1302.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $914M, the 616th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$1.66 on 6 Nov 2026.
Performance Over six months the shares fell 18.2%, against -14.8% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 0.8% over the last twelve months (peer median +9.2%); the operating margin is 12.3% (peer median 11.2%).
Valuation It trades at 23.5× forward earnings against a peer median of 23.6× (9th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.9 points below its cost of capital (8.3% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.44B | HK$1.49B | HK$1.41B | HK$1.40B | HK$1.28B |
| Revenue growth | — | +5% | +1% | +10% | — |
| Gross profit | HK$1.10B | HK$1.08B | HK$1.05B | HK$1.09B | HK$1.00B |
| EBITDA | HK$269M | HK$260M | HK$271M | HK$390M | HK$437M |
| Net income | HK$62.4M | HK$160M | HK$241M | HK$291M | HK$378M |
| Free cash flow | HK$544M | HK$558M | HK$176M | HK$272M | HK$231M |
| Capital expenditure | HK$146M | HK$148M | HK$290M | HK$306M | HK$367M |
| Total debt | n/a | HK$8.95M | HK$5.30M | HK$10.2M | HK$10.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1302.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +27.2% | -5.2% | highest of 21 |
| 6-month return | -18.2% | -14.8% | 10th lowest of 21 |
| Distance from 52-week high | -30.2% | -38.7% | 8th highest of 21 |
| Revenue growth (TTM) | +0.8% | +9.2% | 6th lowest of 21 |
| Operating margin | 12.3% | 11.2% | 10th highest of 21 |
| Forward P/E | 23.5× | 23.6× | 9th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 13.3% | 5.0% | 6th most demanding of 17 |
| Growth delivered (Del g) | +15.5% | +11.5% | 4th highest of 17 |
| Hurdle (Req g minus delivered) | -2.3 pp | -5.0 pp | 7th most demanding of 17 |
| ROIC minus cost of capital | -1.9 pp | +3.6 pp | 6th lowest of 21 |
| EV / EBITDA | 21.1× | 8.9× | 3rd most expensive of 11 |
| Net debt / EBITDA | -5.3× | -0.3× | 2nd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 17.0× | 7.2% | +12.1% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 62.1× | n/a | n/a |